A further retrospective study [53] of 33 colorectal patients with clinical stage T3N0-2M0 and MSI or dMMR tumor was treated with PD-1 inhibitor for 4–10 cycles (median 6), and had a pathological response rate of 100%, with 22/29 (76%) achieving pathological complete response. This evidence concerns the gene PDCD1 and neoplasm.